Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-11-23
pubmed:abstractText
T cell targeting immunotherapy is now considered a possible strategy in acute myelogenous leukaemia (AML), and IFNgamma release may then contribute to the antileukaemic effects. We investigated the effects of IFNgamma on native human AML cells. Normal T cells could be activated to release IFNgamma in the presence of AML cells. Furthermore, high levels of CD119 (IFNgamma receptor alpha chain) expression were observed for all 39 patients examined. Receptor expression was decreased after exposure to exogenous IFNgamma, and receptor ligation caused Stat1 phosphorylation but no phosphorylation of the alternative messengers Erk1/2. The effect of exogenous IFNgamma on AML blast proliferation was dependent on the local cytokine network and IFNgamma (1) inhibited proliferation in the presence of exogenous IL1beta, GM-CSF, G-CSF and SCF; (2) had divergent effects in the presence of IL3 and Flt3 (65 patients examined); (3) inhibited proliferation in the presence of endothelial cells but had divergent effects in the presence of fibroblasts, osteoblasts and normal stromal cells (65 patients examined). IFNgamma increased stress-induced (spontaneous) in vitro apoptosis as well as cytarabine-induced apoptosis only for a subset of patients. Furthermore, IFNgamma decreased the release of proangiogenic CXCL8 and increased the release of antiangiogenic CXCL9-11. We conclude that IFNgamma can be released in the presence of native human AML cells and affect AML cell proliferation, regulation of apoptosis and the balance between pro- and antiangiogenic chemokine release.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/CXCL9 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CXCL9, http://linkedlifedata.com/resource/pubmed/chemical/Chemokines, CXC, http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine, http://linkedlifedata.com/resource/pubmed/chemical/FLT3 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating..., http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage..., http://linkedlifedata.com/resource/pubmed/chemical/IL8 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1beta, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-3, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-8, http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 1, http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 3, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interferon, http://linkedlifedata.com/resource/pubmed/chemical/STAT1 Transcription Factor, http://linkedlifedata.com/resource/pubmed/chemical/STAT1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/fms-Like Tyrosine Kinase 3, http://linkedlifedata.com/resource/pubmed/chemical/interferon gamma receptor
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0340-7004
pubmed:author
pubmed:issnType
Print
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
13-24
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:16612597-Adult, pubmed-meshheading:16612597-Aged, pubmed-meshheading:16612597-Aged, 80 and over, pubmed-meshheading:16612597-Apoptosis, pubmed-meshheading:16612597-Cell Proliferation, pubmed-meshheading:16612597-Chemokine CXCL9, pubmed-meshheading:16612597-Chemokines, CXC, pubmed-meshheading:16612597-Cytarabine, pubmed-meshheading:16612597-Endothelium, Vascular, pubmed-meshheading:16612597-Female, pubmed-meshheading:16612597-Fibroblasts, pubmed-meshheading:16612597-Flow Cytometry, pubmed-meshheading:16612597-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:16612597-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:16612597-Humans, pubmed-meshheading:16612597-Interferon-gamma, pubmed-meshheading:16612597-Interleukin-1beta, pubmed-meshheading:16612597-Interleukin-3, pubmed-meshheading:16612597-Interleukin-8, pubmed-meshheading:16612597-Leukemia, Lymphoid, pubmed-meshheading:16612597-Leukemia, Myeloid, pubmed-meshheading:16612597-Lymphocyte Activation, pubmed-meshheading:16612597-Male, pubmed-meshheading:16612597-Middle Aged, pubmed-meshheading:16612597-Mitogen-Activated Protein Kinase 1, pubmed-meshheading:16612597-Mitogen-Activated Protein Kinase 3, pubmed-meshheading:16612597-Osteoblasts, pubmed-meshheading:16612597-Phosphorylation, pubmed-meshheading:16612597-Receptors, Interferon, pubmed-meshheading:16612597-STAT1 Transcription Factor, pubmed-meshheading:16612597-Signal Transduction, pubmed-meshheading:16612597-Stromal Cells, pubmed-meshheading:16612597-T-Lymphocytes, pubmed-meshheading:16612597-Tumor Cells, Cultured, pubmed-meshheading:16612597-fms-Like Tyrosine Kinase 3
pubmed:year
2007
pubmed:articleTitle
Effects of interferon gamma on native human acute myelogenous leukaemia cells.
pubmed:affiliation
Institute of Medicine, Section for Hematology, The University of Bergen and Haukeland University Hospital, Bergen, Norway. elisabeth.ersvar@med.uib.no
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't